Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:03:26.524Z.
Calculation as of: 2026-10-06T17:03:26.524Z.
Quote observation: 2026-10-06T17:00:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c752279377b025acf72c3dd079155b3811244be546b74823e0a9f28be94cffb5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$44.18M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$43.17M
EV/EBIT Ratio
80.38x
TTM Avg
44.61x
3Y Avg
49.72x
5Y Avg
49.72x
Market Cap
$43.16M
EV/EBIT Ratio
N/A
TTM Avg
7.97x
3Y Avg
11.01x
5Y Avg
11.01x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nano-X Imaging Ltd. (NNOX) | $43.71M | N/A | N/A | N/A | N/A |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $44.18M | N/A | N/A | N/A | N/A |
| SANUWAVE Health Inc. (SNWV)vs › | $43.17M | 80.38x | 44.61x | 49.72x | 49.72x |
| CVRx, Inc. (CVRX)vs › | $44.51M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $43.16M | N/A | 7.97x | 11.01x | 11.01x |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $45.20M | N/A | N/A | N/A | N/A |
| Precipio, Inc. (PRPO)vs › | $42.11M | N/A | N/A | N/A | N/A |
| DarioHealth Corp. (DRIO)vs › | $45.37M | N/A | 17.26x | 19.56x | 25.78x |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.44M | N/A | N/A | N/A | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.09M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
